SBRX12

SBRX12 is a plant-based drug candidate being developed by Stramsen Biotech for the treatment of gastric acid disorders, including heartburn, stomach ulcers, and *Helicobacter pylori* (*H. pylori*) infections. The therapeutic is designed to control gastric acid production, protect the gastric lining from acid damage, and exert antibacterial effects against *H. pylori*, a bacterium known to cause ulcers. As part of Stramsen Biotech's proprietary pipeline of herbal therapeutics, SBRX12 leverages medicinal plant compounds to provide a natural approach to managing gastrointestinal conditions. Stramsen Biotech is a Texas-based biopharmaceutical company that utilizes a proprietary database of medicinal plants to develop its candidates.